Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The Company's lead in-licensed compound, emricasan, is being developed in collaboration with Novartis for the treatment of patients with NASH-driven chronic liver diseases. In addition, Conatus' lead internally developed compound, CTS-2090, is targeting the treatment of patients with chronic diseases involving inflammasome pathways. Source
No articles found.
Castle Biosciences is a skin cancer diagnostics company focused on providing physi...
Castle Biosciences is a skin cancer diagnostics...
Precision BioSciences is dedicated to improving life (DTIL) through its proprietar...
Precision BioSciences is dedicated to improving...
Melinta Therapeutics, Inc. is dedicated to saving lives threatened by the global p...
Melinta Therapeutics, Inc. is dedicated to savi...
Ra PharmaÂŽ is a clinical-stage biopharmaceutical company using a proprietary pept...
Ra PharmaÂŽ is a clinical-stage biopharmaceutic...
Morphic Therapeutic is leading the development of a new generation of oral integri...
Morphic Therapeutic is leading the development ...
Translate Bio is a leading mRNA therapeutics company developing a new class of pot...
Translate Bio is a leading mRNA therapeutics co...
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing th...
Cyclerion Therapeutics is a clinical-stage biop...
Join the National Investor Network and get the latest information with your interests in mind.